Plasmapheresis reverses all side-effects of a cisplatin overdose - A case report and treatment recommendation

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Hofmann, Guenter ^a   Bauernhofer, Thomas ^a   Krippl, Peter ^a   Lang Loidolt, Doris ^a   Horn, Sabine ^a   Goessler, Walter ^b   Schippinger, Walter ^a   Ploner, Ferdinand ^a   Stoeger, Herbet ^a   Samonigg, Hellmut ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; HEPARIN; METOCLOPRAMIDE; NEUROLEPTIC AGENT; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CASE REPORT; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; FEMALE; HEARING LOSS; HUMAN; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDICAL RECORD; MEDICATION ERROR; NAUSEA; PLASMAPHERESIS; POSTOPERATIVE CARE; PRACTICE GUIDELINE; TINNITUS; TREATMENT OUTCOME; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; ENZYMOLOGY; HEARING IMPAIRMENT; KIDNEY FAILURE; LIVER; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; TIME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HEARING LOSS; HUMANS; LIVER; LUNG NEOPLASMS; MIDDLE AGED; NAUSEA; PLASMAPHERESIS; RENAL INSUFFICIENCY; TIME FACTORS; VOMITING;

EID: 30444447630     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-1     Document Type: Article

References (25)

1. Markman M: Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2003, 2(6):597-607.
2. Hartmann JT, Lipp HP: Toxicity of platinum compounds. Expert Opin Pharmacother 2003, 4(6):889-901.
3. Pike IM, Arbus MH: Cisplatin overdosage. J Clin Oncol 1992, 10(9):1503-1504.
4. Blakley BW, Cohen JI, Doolittle ND, Muldoon LL, Campbell KC, Dickey DT, Neuwelt EA: Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope 2002, 112(11):1997-2001.
5. Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE et al: Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 1997, 3(6):331-340.
6. Lagrange JL, Cassuto-Viguier E, Barbe V, Fischel JL, Mondain JR, Etienne MC, Ferrero JM, Creisson-Ducray A, Formento P, Milano G: Cytotoxic effects of long-term circulating ultrafiltrable platinum species and limited efficacy of haemodialysis in clearing them. Eur J Cancer 1994, 30A(14):2057-2060.
7. Brivet F, Pavlovitch JM, Gouyette A, Cerrina ML, Tchernia G, Dormont J: Inefficiency of early prophylactic hemodialysis in cis-platinum overdose. Cancer Chemother Pharmacol 1986, 18(2):183-184.
8. Chu G, Mantin R, Shen YM, Baskett G, Sussman H: Massive cisplatin overdose by accidental substitution for carboplatin. Toxicity and management. Cancer 1993, 72(12):3707-3714.
9. Charlier C, Kintz P, Dubois N, Plomteux G: Fatal overdosage with cisplatin. J Anal Toxicol 2004, 28(2):138-140.
10. Sheikh-Hamad D, Timmins K, Jalali Z: Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 1997, 8(10):1640-1644.
11. Wu YJ, Muldoon LL, Neuwelt EA: The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 2005, 312(2):424-431.
12. Erdlenbruch B, Pekrun A, Schiffmann H, Witt O, Lakomek M: Topical topic: accidental cisplatin overdose in a child: reversal of acute renal failure with sodium thiosulfate. Med Pediatr Oncol 2002, 38(5):349-352.
13. Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G: High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope 2004, 114(9):1660-1667.
14. Sastry J, Kellie SJ: Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose Cisplatin and amifostine. Pediatr Hematol Oncol 2005, 22(5):441-445.
15. ASHP guidelines on preventing medication errors with antineoplastic agents. Am J Health Syst Pharm 2002, 59(17):1648-1668.
16. Criteria for facilities and personnel for the administration of parenteral systemic antineoplastic therapy. Adopted on March 3, 2004 by the American Society of Clinical Oncology. J Clin Oncol 2004, 22 (22):4613-4615.
17. Womer RB, Tracy E, Soo-Hoo W. Bicker B, DiTaranto S, Barnsteier JH: Multidisciplinary systems approach to chemotherapy safety: rebuildig processes and holding the gains. J Clin Oncol 2002, 20 (24):4705-4712.
18. Pourrat X, Antier D, Crenn I, Calais G, Jonville-Bera AP, Rouleau A: A prescription and administration error of cisplatin: a case report. Pharm World Sci 2004, 26(2):64-65.
19. Choi JH, Oh JC, Kim KH, Chong SY, Kang MS, Oh do Y: Successful treatment of cisplatin overdose with plasma exchange. Yonsei Med J 2002, 43(1): 128-132.
20. Jug HK, Lee J, Lee SN: A case of massive cisplatin overdose managed by plasmapheresis. Korean J Intern Med 1995, 10(2):105-154.
21. Linenberger ML, Price TH: Use of cellular and plasma apheresis in the critically ill patient: part 1: technical and physiological considerations. J Intesive Care Med 2005, 20(1):18-27.
22. Lineberger ML, Price TH: Use of cellular and plasma apheresis in the critically ill patient: Part II: Clinical indications and applicatios. J Instensive Care Med 2005, 20(2):88-103
23. Stegmayr B, Wikdahl AM: Access in the therapeutic apheresis. Ther Apher Dial 2003, 7(2):209-214.
24. Mallat SG, Ismail N: Plasmapheresis and related techniques: what should we know. J Med Liban 2002, 50(1-2):45-49.
25. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG: Using serum creatinine to estimate glomerular filtration rate: accuracy in good health ad in chronic kidney disease. Ann Intern Med 2004, 141 (12):929-937.